Song Sarah
Department of Neurology, Rush University Medical Center, Chicago, Illinois.
Semin Neurol. 2013 Nov;33(5):427-35. doi: 10.1055/s-0033-1364213. Epub 2014 Feb 6.
Stroke is a devastating disease and currently the fourth leading cause of death in this country. Acute ischemic stroke is an emergency and requires effective triage, diagnosis, and critical management. The hyperacute management of ischemic stroke begins in the field, with recognition of stroke symptoms by emergency medical systems (EMS) personnel. The EMS is an important component to an effective stroke system of care, which also includes primary stroke centers, routing protocols for acute ischemic stroke, and telemedicine. Following the arrival of a potential stroke patient to the emergency room setting, patients should be stabilized and undergo assessment for potential intravenous alteplase (IV tPA) treatment. Assessments include diagnostic tests, neuroimaging, and standardized stroke evaluations. After these assessments have been performed, IV tPA, the only medication for acute stroke approved by the U.S. Food and Drug Administration, can be considered using a variety of inclusion and exclusion criteria. Previously time restrictions limited the usage of IV tPA to 3 hours, but this time window has now been extended for eligible candidates to 4.5 hours. The administration of IV tPA has specific requirements for monitoring and should be standardized via protocol across hospitals.
中风是一种极具破坏性的疾病,目前是该国第四大死因。急性缺血性中风是一种急症,需要有效的分诊、诊断和重症管理。缺血性中风的超急性管理始于现场,由紧急医疗系统(EMS)人员识别中风症状。EMS是有效中风护理系统的重要组成部分,该系统还包括初级中风中心、急性缺血性中风的转诊协议和远程医疗。潜在中风患者到达急诊室后,应使其病情稳定,并接受潜在静脉注射阿替普酶(IV tPA)治疗的评估。评估包括诊断测试、神经影像学检查和标准化中风评估。在进行这些评估后,可根据各种纳入和排除标准考虑使用IV tPA,这是美国食品药品监督管理局批准的唯一用于急性中风的药物。以前时间限制将IV tPA的使用限制在3小时以内,但现在这个时间窗口已扩大到符合条件的患者可延长至4.5小时。IV tPA的给药有特定的监测要求,应通过各医院的方案进行标准化。